Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Maria Norrby,Timo Vesikari,Lars Lindqvist,Markus Maeurer,Raija Ahmed,Shahnaz Mahdavifar,Sean Bennett,J. Bruce McClain,Barbara Shepherd, Daner Li,David A. Hokey,Ingrid Kromann,Søren T. Hoff,Peter Andersen,Adriëtte W. de Visser,Simone A. Joosten,Tom H. M. Ottenhoff,Jan Andersson,Susanna Brighenti

Vaccine（2017）

引用 42|浏览46

暂无评分

摘要

•H4:IC31 vaccination was well tolerated with an acceptable safety profile.•H4:IC31 vaccination elicited persistent antigen-specific CD4+ T cell responses.•H4:IC31 triggered T cell expansion, IFNγ production and multifunctional Th1 cells.•Optimal antigen-adjuvant doses were 5, 15, or 50 μg of H4 plus 500 nmol of IC31.

查看译文

关键词

TB,Mtb,BCG,MDR,TST,ICS,FASCIA,AE,INR,MHC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要